Vivos Therapeutics (VVOS) Depreciation & Amortization (CF) (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $454000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 156.5% year-over-year to $454000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 159.15% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 125.3% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $454000.0, up from $442000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for VVOS reached as high as $454000.0 in Q1 2026 and fell as low as $41000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $213764.7 across 5 years, with a median of $169000.0 in 2022.
• Across the five-year window, Depreciation & Amortization (CF) tumbled 76.84% in 2022 and soared 326.83% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $169000.0 in 2022, then dropped by 11.83% to $149000.0 in 2023, then retreated by 3.36% to $144000.0 in 2024, then surged by 206.94% to $442000.0 in 2025, then advanced by 2.71% to $454000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $454000.0 in Q1 2026, $442000.0 in Q4 2025, and $384000.0 in Q3 2025.